ISSN: 1618-7598
Journal Home
Journal Guideline
European Journal of Health Economics Q1 Unclaimed
European Journal of Health Economics is a journal indexed in SJR in Economics, Econometrics and Finance (miscellaneous) and Health Policy with an H index of 71. It has a price of 2990 €. It has an SJR impact factor of 1,063 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,063.
European Journal of Health Economics focuses its scope in these topics and keywords: treatment, health, cancer, changing, colorectal, costs, effects, model, state, strategies, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy:
Type of publications:
Publication frecuency: -
2990 €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
1,063
SJR Impact factor71
H Index159
Total Docs (Last Year)342
Total Docs (3 years)7873
Total Refs1212
Total Cites (3 years)309
Citable Docs (3 years)3.29
Cites/Doc (2 years)49.52
Ref/DocOther journals with similar parameters
American Economic Journal: Applied Economics Q1
American Economic Journal: Economic Policy Q1
Journal of the European Economic Association Q1
American Economic Journal: Microeconomics Q1
Journal of Supply Chain Management Q1
Compare this journals
Aims and Scope
Best articles by citations
The assessment of the economic return from controlled clinical trials
View moreComparison of general practitioner records and patient self-report questionnaires for estimation of costs
View moreImpact of unemployment on self-perceived health
View moreDo physicians accept quality of life and utility measurement?
View moreEconomic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy
View moreA comparison of the EuroQol and the Health Utilities Index in patients treated for congenital anomalies
View moreMetal on metal hip resurfacing arthroplasty
View moreExponential health utility
View moreA pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor
View moreEconomic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK
View moreCost-utility of interferon beta 1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis
View moreEconomic evaluation of human papillomavirus screening in Germany
View moreIs therapeutic innovation responsible for the increase in drug expenditure?
View moreInfluence of surgical and treatment choices on the cost of breast cancer care
View moreGemeindenahe stationäre Versorgung fur Schizophreniepatienten
View moreThe reimbursable incontinence pads market for outpatients in five European countries
View moreThe role of prices in drug expenditure analysis
View moreHealth-related quality of life of patients with overactive bladder receiving immediate-release tolterodine
View morePrevalence and treatment costs of type 2 diabetes in Germany and the effects of social and demographical differences
View moreFinancial incentives and the supply of laboratory tests
View moreProject of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines
View moreExamining the determinants of drug launch delay in pre-TRIPS India
View moreThe heterogeneity of markets for drugs in Europe
View moreMedical and economic evaluation of an integrated system of automated analysis in cellular hematology (Sysmex HST-330)
View more
Comments